Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and manufacturing capabilities at a single site, creating a seamless pathway from early discovery through GMP manufacturing for clinical supply of complex protein therapeutics.

Supported by an €18 million loan from the European Investment Bank (EIB), backed by the InvestEU program, and combined with Icosagen’s own funding, the initiative represents a total investment of €45 million. The program included the establishment of a new state-of-the-art single-use GMP manufacturing facility, operating in accordance with European GMP regulatory requirements.

The expansion enables Icosagen to support biotechnology and biopharmaceutical companies globally across discovery, developability assessment, CMC development and Phase I/II GMP manufacturing within one integrated organization and at a single site.

“The completion of this investment program represents an important strategic milestone for Icosagen,” said Prof. Mart Ustav, Founder and CEO of Icosagen. “It strengthens our ability to connect early therapeutic protein development with CMC and GMP manufacturing in one integrated pathway, with fewer handovers and a deeper understanding of each molecule from the start.”

“Strengthening Europe’s biotechnology value chain is essential for our competitiveness and resilience,” said EIB Vice-President Karl Nehammer. “With this investment, the EIB is supporting a fully integrated model that connects discovery to clinical manufacturing in one place - helping European innovators bring complex biologics to patients faster, while reducing reliance on external manufacturing capacities.”

For nearly three decades, Icosagen has developed technologies and scientific expertise for the discovery, engineering, expression, purification, and analytical characterization of therapeutic proteins, antibodies, and complex recombinant biologics. The company employs more than 200 scientists and has extensive experience in technically demanding biologic modalities, including multi-specific antibodies and antibody-derived formats.

The recent expansion allows Icosagen to offer a holistic, integrated approach to our clients which includes antibody discovery, protein engineering, transient expression, developability assessment, stable IcoCell® CHO cell line development, upstream and downstream process development, analytical characterization and GMP manufacturing.

This model is particularly suited for emerging complex biologic modalities that do not fit conventional platform approaches. By integrating early developability and manufacturability considerations before starting formal CMC development, Icosagen identifies and reduces technical risks earlier, shortens its clients’ development timelines, and helps avoid costly late-stage manufacturing challenges.

“We help clients develop non-standard antibody and protein modalities without losing the original biological intent of the molecule,” said Prof. Ustav. “For complex candidates, the goal is not to force every molecule into a conventional template, but to build a development and manufacturing strategy that fits the biology.”

As an independent, family-owned company operating on the principle of organic growth, Icosagen combines scientific depth with an agile development model, designed to support innovative biologic programs from concept to clinical manufacturing.